Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke
Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a compar...
Gespeichert in:
| Veröffentlicht in: | Stroke (1970) 2011-09, Vol.42 (9), p.2633-2635 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2635 |
|---|---|
| container_issue | 9 |
| container_start_page | 2633 |
| container_title | Stroke (1970) |
| container_volume | 42 |
| creator | SWITZER, Jeffrey A HESS, David C ERGUL, Adviye WALLER, Jennifer L MACHADO, Livia S PORTIK-DOBOS, Vera CREED PETTIGREW, L CLARK, Wayne M FAGAN, Susan C |
| description | Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P |
| doi_str_mv | 10.1161/STROKEAHA.111.618215 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_886598486</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>886598486</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-ceb7f8d276c8b9507af35f477ebea1014785ab08d5b50309f34881b993aeaf9a3</originalsourceid><addsrcrecordid>eNpFkE1vEzEQhi0EoqHlHyDkC-K0rb221_YxqlIa0agSTc-rWWcMBmcdbAc1_55FCe1pNNLzzsdDyAfOLjnv-NXD-tv918X8dj61_LLjpuXqFZlx1cpGdq15TWaMCdu00toz8q6Un4yxVhj1lpy1XAttmJmR7yuoOTzRFVaIMe1yqhhGKNhYGkYKI1087WLKUFM-0HUOEGnydDnWDH9wTPtCV2FM7uBiGJH6lOnc7SvSZXE_cBscfag5_cIL8sZDLPj-VM_J481ifX3b3N1_WV7P7xonhaiNw0F7s2l158xgFdPghfJSaxwQOONSGwUDMxs1KCaY9UIawwdrBSB4C-KcfD7OnT75vcdS-20oDmOEEadje2M6ZY003UTKI-lyKiWj73c5bCEfes76f4b7Z8NTy_uj4Sn28bRgP2xx8xz6r3QCPp0AKA6izzC6UF44qZjsNBN_AXCShdM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>886598486</pqid></control><display><type>article</type><title>Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>SWITZER, Jeffrey A ; HESS, David C ; ERGUL, Adviye ; WALLER, Jennifer L ; MACHADO, Livia S ; PORTIK-DOBOS, Vera ; CREED PETTIGREW, L ; CLARK, Wayne M ; FAGAN, Susan C</creator><creatorcontrib>SWITZER, Jeffrey A ; HESS, David C ; ERGUL, Adviye ; WALLER, Jennifer L ; MACHADO, Livia S ; PORTIK-DOBOS, Vera ; CREED PETTIGREW, L ; CLARK, Wayne M ; FAGAN, Susan C</creatorcontrib><description>Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).
Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.111.618215</identifier><identifier>PMID: 21737808</identifier><identifier>CODEN: SJCCA7</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Aged ; Anti-Bacterial Agents - administration & dosage ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Brain Ischemia - blood ; Brain Ischemia - drug therapy ; Female ; Fibrinolytic Agents - administration & dosage ; Humans ; Infusions, Intravenous ; Male ; Matrix Metalloproteinase 9 - blood ; Matrix Metalloproteinase Inhibitors ; Medical sciences ; Middle Aged ; Minocycline - administration & dosage ; Neurology ; Pharmacology. Drug treatments ; Stroke - blood ; Stroke - drug therapy ; Thrombolytic Therapy - methods ; Tissue Plasminogen Activator - administration & dosage ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>Stroke (1970), 2011-09, Vol.42 (9), p.2633-2635</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-ceb7f8d276c8b9507af35f477ebea1014785ab08d5b50309f34881b993aeaf9a3</citedby><cites>FETCH-LOGICAL-c433t-ceb7f8d276c8b9507af35f477ebea1014785ab08d5b50309f34881b993aeaf9a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3685,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24504670$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21737808$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SWITZER, Jeffrey A</creatorcontrib><creatorcontrib>HESS, David C</creatorcontrib><creatorcontrib>ERGUL, Adviye</creatorcontrib><creatorcontrib>WALLER, Jennifer L</creatorcontrib><creatorcontrib>MACHADO, Livia S</creatorcontrib><creatorcontrib>PORTIK-DOBOS, Vera</creatorcontrib><creatorcontrib>CREED PETTIGREW, L</creatorcontrib><creatorcontrib>CLARK, Wayne M</creatorcontrib><creatorcontrib>FAGAN, Susan C</creatorcontrib><title>Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).
Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.</description><subject>Aged</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Brain Ischemia - blood</subject><subject>Brain Ischemia - drug therapy</subject><subject>Female</subject><subject>Fibrinolytic Agents - administration & dosage</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Matrix Metalloproteinase 9 - blood</subject><subject>Matrix Metalloproteinase Inhibitors</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Minocycline - administration & dosage</subject><subject>Neurology</subject><subject>Pharmacology. Drug treatments</subject><subject>Stroke - blood</subject><subject>Stroke - drug therapy</subject><subject>Thrombolytic Therapy - methods</subject><subject>Tissue Plasminogen Activator - administration & dosage</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1vEzEQhi0EoqHlHyDkC-K0rb221_YxqlIa0agSTc-rWWcMBmcdbAc1_55FCe1pNNLzzsdDyAfOLjnv-NXD-tv918X8dj61_LLjpuXqFZlx1cpGdq15TWaMCdu00toz8q6Un4yxVhj1lpy1XAttmJmR7yuoOTzRFVaIMe1yqhhGKNhYGkYKI1087WLKUFM-0HUOEGnydDnWDH9wTPtCV2FM7uBiGJH6lOnc7SvSZXE_cBscfag5_cIL8sZDLPj-VM_J481ifX3b3N1_WV7P7xonhaiNw0F7s2l158xgFdPghfJSaxwQOONSGwUDMxs1KCaY9UIawwdrBSB4C-KcfD7OnT75vcdS-20oDmOEEadje2M6ZY003UTKI-lyKiWj73c5bCEfes76f4b7Z8NTy_uj4Sn28bRgP2xx8xz6r3QCPp0AKA6izzC6UF44qZjsNBN_AXCShdM</recordid><startdate>20110901</startdate><enddate>20110901</enddate><creator>SWITZER, Jeffrey A</creator><creator>HESS, David C</creator><creator>ERGUL, Adviye</creator><creator>WALLER, Jennifer L</creator><creator>MACHADO, Livia S</creator><creator>PORTIK-DOBOS, Vera</creator><creator>CREED PETTIGREW, L</creator><creator>CLARK, Wayne M</creator><creator>FAGAN, Susan C</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110901</creationdate><title>Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke</title><author>SWITZER, Jeffrey A ; HESS, David C ; ERGUL, Adviye ; WALLER, Jennifer L ; MACHADO, Livia S ; PORTIK-DOBOS, Vera ; CREED PETTIGREW, L ; CLARK, Wayne M ; FAGAN, Susan C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-ceb7f8d276c8b9507af35f477ebea1014785ab08d5b50309f34881b993aeaf9a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Brain Ischemia - blood</topic><topic>Brain Ischemia - drug therapy</topic><topic>Female</topic><topic>Fibrinolytic Agents - administration & dosage</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Matrix Metalloproteinase 9 - blood</topic><topic>Matrix Metalloproteinase Inhibitors</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Minocycline - administration & dosage</topic><topic>Neurology</topic><topic>Pharmacology. Drug treatments</topic><topic>Stroke - blood</topic><topic>Stroke - drug therapy</topic><topic>Thrombolytic Therapy - methods</topic><topic>Tissue Plasminogen Activator - administration & dosage</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SWITZER, Jeffrey A</creatorcontrib><creatorcontrib>HESS, David C</creatorcontrib><creatorcontrib>ERGUL, Adviye</creatorcontrib><creatorcontrib>WALLER, Jennifer L</creatorcontrib><creatorcontrib>MACHADO, Livia S</creatorcontrib><creatorcontrib>PORTIK-DOBOS, Vera</creatorcontrib><creatorcontrib>CREED PETTIGREW, L</creatorcontrib><creatorcontrib>CLARK, Wayne M</creatorcontrib><creatorcontrib>FAGAN, Susan C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SWITZER, Jeffrey A</au><au>HESS, David C</au><au>ERGUL, Adviye</au><au>WALLER, Jennifer L</au><au>MACHADO, Livia S</au><au>PORTIK-DOBOS, Vera</au><au>CREED PETTIGREW, L</au><au>CLARK, Wayne M</au><au>FAGAN, Susan C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2011-09-01</date><risdate>2011</risdate><volume>42</volume><issue>9</issue><spage>2633</spage><epage>2635</epage><pages>2633-2635</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><coden>SJCCA7</coden><abstract>Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage.
The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group.
Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019).
Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>21737808</pmid><doi>10.1161/STROKEAHA.111.618215</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0039-2499 |
| ispartof | Stroke (1970), 2011-09, Vol.42 (9), p.2633-2635 |
| issn | 0039-2499 1524-4628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_886598486 |
| source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Anti-Bacterial Agents - administration & dosage Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Brain Ischemia - blood Brain Ischemia - drug therapy Female Fibrinolytic Agents - administration & dosage Humans Infusions, Intravenous Male Matrix Metalloproteinase 9 - blood Matrix Metalloproteinase Inhibitors Medical sciences Middle Aged Minocycline - administration & dosage Neurology Pharmacology. Drug treatments Stroke - blood Stroke - drug therapy Thrombolytic Therapy - methods Tissue Plasminogen Activator - administration & dosage Vascular diseases and vascular malformations of the nervous system |
| title | Matrix Metalloproteinase-9 in an Exploratory Trial of Intravenous Minocycline for Acute Ischemic Stroke |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T20%3A24%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Matrix%20Metalloproteinase-9%20in%20an%20Exploratory%20Trial%20of%20Intravenous%20Minocycline%20for%20Acute%20Ischemic%20Stroke&rft.jtitle=Stroke%20(1970)&rft.au=SWITZER,%20Jeffrey%20A&rft.date=2011-09-01&rft.volume=42&rft.issue=9&rft.spage=2633&rft.epage=2635&rft.pages=2633-2635&rft.issn=0039-2499&rft.eissn=1524-4628&rft.coden=SJCCA7&rft_id=info:doi/10.1161/STROKEAHA.111.618215&rft_dat=%3Cproquest_cross%3E886598486%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=886598486&rft_id=info:pmid/21737808&rfr_iscdi=true |